Saturday 17 October 2026 Export CCEL’s income statement to Excel — free account

Cryo-Cell International Inc.

Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024. In the quarter to August 2026, revenue was flat, EPS grew 77.8%, free cash flow fell 58.4% and total debt fell 29.5%, each against the same quarter a year earlier.

4.42 0.77 +21.10%

Follow CCEL

Alert me

Market cap: $29.4M
P/E: 0.0×
Fwd P/E: 43.8×
Dividend yield: 0.00%
F-score: 6/9
Altman Z: −0.23
Beneish M: −3.17
Dividend safety: 20/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 47.91%

Capital & Financial Ratios $m

Market Cap 29.43

Revenue 31.13

Net Income (1.95)

Free Cash Flow 4.65

Net Debt 3.81

Current Ratio 0.86

Debt/Equity (0.49)

P/E ratio 0.00

Fwd P/E 43.80

P/S ratio 1.14

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 136.67%

Next Y EPS Growth (81.82%)

Next Y revenue growth (4.84%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 12.16%

10-year low 10-year high

EV/Sales against its own 10 years 14.63%

10-year low 10-year high

EV/FCF against its own 10 years 77.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2025	0.40	0.25 0.15
2024	0.25	0.25
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	3	3	4
Receivables	7	7	7	7
Inventory	1	1	0	1
Other	1	0	1	1
	9	13	12	13

	2023	2024	2025	Q'26
Payables	3	2	3	2
ST’ Debt	1	4	2	—
Other	1	—	—	—
	21	22	20	15

Compound Annual Growth %

	10y	5y	3y
Sales	4.11%	0.27%	1.33%
Cash Flow	1.22%	(8.34%)	(13.86%)
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Feb	May	Aug	Nov	Year
’26	8	8	8	—	—
’25	8	8	8	8	32
’24	8	8	8	8	32
’23	8	8	8	8	31
’22	7	8	8	8	30
’21	7	7	8	7	29
’20	8	8	8	8	31

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	1	2	1	—	—
’25	1	1	3	1	5
’24	0	2	2	2	6
’23	2	2	2	3	9
’22	2	2	3	2	9
’21	3	2	2	2	8
’20	3	1	2	3	8

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	1	2	1	—	—
’25	1	1	2	1	5
’24	(1)	(1)	2	2	2
’23	1	0	(1)	1	1
’22	(4)	2	(9)	4	(7)
’21	3	(3)	1	1	1
’20	3	1	2	3	8

Fiscal quarters ending in the months shown.

EPS $

	Feb	May	Aug	Nov	Year
’26	0.01	0.07	0.16	—	—
’25	0.03	0.04	0.09	(0.47)	(0.30)
’24	0.07	0.08	0.13	(0.23)	0.05
’23	0.09	0.03	0.08	(1.34)	(1.14)
’22	0.10	0.07	0.06	0.10	0.33
’21	0.08	0.14	0.10	(0.08)	0.25
’20	0.08	0.12	0.10	0.15	0.45

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.55	4.20	6.03	5.50	4.52	7.36	4.10	2.69	4.47	3.19	Analyst estimates 2026–2028 Powerpack
	High	4.56	9.67	9.98	8.90	9.93	14.16	11.84	7.25	9.50	8.79
People
People	Employees	75	81	101	97	98	93	88	88	86	76
	Revenue/emp, $m	0.31	0.31	0.29	0.33	0.32	0.31	0.34	0.36	0.37	0.42
Income, $m
Income, $m	Revenue	23	25	29	32	31	29	30	31	32	32
	Gross margin, %	75.03	73.51	70.77	68.46	68.99	68.88	71.02	73.23	75.15	76.63
	EBT	(2)	4	4	3	5	3	3	(13)	3	(2)
	EBT margin, %	(10.72)	14.28	12.38	10.66	16.18	9.04	10.94	(42.64)	8.77	(7.40)
	Net income	(1)	2	(1)	2	4	2	3	(10)	0	(2)
	Depreciation	2	0	0	1	1	1	2	2	1	1
Per share, $
Per share, $	Revenue	2.85	3.59	3.92	4.08	4.13	3.55	3.58	3.76	3.93	3.91
	Earnings	(0.16)	0.33	(0.11)	0.29	0.45	0.26	0.33	(1.14)	0.05	(0.30)
	Cash flow	0.61	0.81	0.71	0.81	1.12	0.97	1.01	1.07	0.74	0.68
	Capex	(0.04)	(0.01)	(0.09)	(0.08)	(0.06)	(0.85)	(1.81)	(0.92)	(0.44)	(0.01)
	Free cash flow	0.57	0.80	0.63	0.72	1.06	0.12	(0.79)	0.15	0.30	0.66
	Book value	(1.90)	(1.77)	(1.19)	(0.89)	(0.35)	0.51	(0.18)	(1.32)	(1.63)	(2.31)
	Shares, m	8	7	7	8	8	8	8	8	8	8
Valuation, ×
Valuation, ×	P/E	0.00	24.42	0.00	26.32	15.96	47.62	12.85	0.00	170.80	0.00
	P/S	1.49	2.24	1.87	1.85	1.82	3.49	1.22	1.42	2.17	1.02
	P/B	0.00	0.00	0.00	0.00	0.00	24.07	0.00	0.00	0.00	0.00
	EV/Sales	1.65	2.19	1.97	1.80	1.68	3.30	1.52	1.70	2.43	1.24
	EV/FCF	8.22	9.88	12.28	10.54	6.53	97.67	(6.86)	41.61	36.33	10.08
Cash, $m
Cash, $m	Operating cash flow	5	6	5	6	8	8	9	9	6	5
	Capex	0	0	(1)	(1)	0	(7)	(15)	(8)	(4)	0
	Free cash flow	5	6	5	6	8	1	(7)	1	2	5
Balance, $m
Balance, $m	Working capital	(4)	(1)	(1)	0	2	(5)	(10)	(11)	(9)	(8)
	Total debt	10	7	13	9	6	3	11	10	12	10
	Net debt	6	1	6	2	(4)	(6)	9	9	8	7
	Shareholders’ equity	(15)	(13)	(9)	(7)	(3)	4	(2)	(11)	(13)	(19)
Returns, %
Returns, %	ROA	(6.77)	10.66	(2.58)	5.37	8.14	3.90	4.41	(15.10)	0.64	(3.84)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	33.07	0.00	0.00	0.00
	ROE	12.96	(16.59)	7.98	(28.89)	(75.37)	274.29	208.38	151.67	(3.32)	15.27

Negative figures in brackets.

All 10 years →

Fiscal years to Nov 2025 · latest quarter Aug 2026 · fundamentals updated 15 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AIRS AirSculpt Technologies, Inc.	$102.0M	— (loss-making)	— (loss-making)	−2.53% (below 0%: shrinking)	n/m	−131.07% (below 0%: shrinking)	61.38%	(0.07%)	Compare
JYNT The Joint Corp.	$97.7M	26.0×	16.9×	+14.41% (above 0%: growing)	+400.00% (above 0%: growing)	+432.31% (above 0%: growing)	83.68%	(2.43%)	Compare
PARK Park Dental Partners, Inc.	$91.3M	— (loss-making)	—	+12.15% (above 0%: growing)	−65.84% (below 0%: shrinking)	−34.78% (below 0%: shrinking)	14.37%	1.90%	Compare
BTMD biote Corp.	$39.9M	6.8×	11.0×	−9.48% (below 0%: shrinking)	n/m	−174.16% (below 0%: shrinking)	65.38%	(7.93%)	Compare
PIII P3 Health Partners Inc.	$30.1M	— (loss-making)	—	+8.60% (above 0%: growing)	n/m	−272.24% (below 0%: shrinking)	22.26%	10.67%	Compare
CCEL Cryo-Cell International Inc.	$29.4M	— (loss-making)	43.8×	−0.02% (below 0%: shrinking)	+77.78% (above 0%: growing)	−58.37% (below 0%: shrinking)	79.38%	28.04%
DCGO DocGo Inc.	$27.9M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−132.28% (below 0%: shrinking)	30.52%	(24.41%)	Compare
PAIYY Aesthetic Medical International Hldngs Group Ltd Sponsored ADR	$15.9M	— (loss-making)	8.3×	+25,427.42% (above 0%: growing)	n/m	−206.36% (below 0%: shrinking)	42.70%	(1.24%)	Compare
CCM Concord Medical Services Holdings Limited	$10.5M	— (loss-making)	— (loss-making)	+37.65% (above 0%: growing)	n/m	−281.45% (below 0%: shrinking)	(13.15%)	0.00%	Compare
Median of peers	$35.0M	—	11.0×	+10.38%	—	−153.22%	36.61%	(0.65%)

All 55 Medical Care Facilities stocks →

Cryo-Cell International Inc. (CCEL) key facts

Concern: Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024.
Cryo-Cell International Inc. (CCEL) is a Medical Care Facilities company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, CCEL traded at $4.42, a market capitalization of $29.4 million.
Return on equity was 15.3% and debt-to-equity -0.49.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −0.23 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 15, 2026.